ACE-031 (1mg)

$69.00

1 Unit
$69 per unit
$69.00
2 Units
$67.28 per unit (save 2% per unit)
$134.56
$138.00
3 Units
$65.55 per unit (save 5% per unit)
$196.65
$207.00
4 Units
$63.83 per unit (save 7% per unit)
$255.32
$276.00
5 Units
$62.1 per unit (save 10% per unit)
$310.50
$345.00
6 Units
$60.38 per unit (save 12% per unit)
$362.28
$414.00
7 Units
$58.65 per unit (save 15% per unit)
$410.55
$483.00
8 Units
$56.93 per unit (save 17% per unit)
$455.44
$552.00
9 Units
$55.2 per unit (save 20% per unit)
$496.80
$621.00
10 Units
$53.48 per unit (save 22% per unit)
$534.80
$690.00
Category:

Description

ACE-031 peptide is a synthetic fusion protein designed to inhibit myostatin, a natural protein that limits muscle growth.  By blocking myostatin and related ligands like activin, ACE-031 promotes significant increases in muscle mass and strength, with studies showing up to a 40% increase in muscle volume in animal models and 3–3.4% gains in lean body mass and bone density in human trials.

Key Health Benefits:
Muscle Growth & Strength: Inhibits myostatin to stimulate muscle cell proliferation, enhancing muscle mass and physical performance.
Bone Health: Improves bone mineral density, with up to a 3.4% increase in lumbar spine density in postmenopausal women and significant gains in femur and vertebral bone density.
Metabolic & Energy Benefits: Enhances muscle oxidative capacity, reduces fatigue, and may improve energy metabolism and vascularization of muscle tissue.
Muscle Wasting Conditions: Shows promise in treating Duchenne muscular dystrophy (DMD), sarcopenia (age-related muscle loss), and other neuromuscular disorders by slowing muscle degeneration and improving function.
Recovery & Rehabilitation: Supports faster recovery from injuries and surgeries by promoting muscle repair and reducing atrophy.
Osteoporosis Prevention: Increased muscle mass helps maintain bone density, reducing fracture risk, especially in elderly or inactive individuals.
Additional Notes:
Clinical Status: While early-phase trials showed efficacy, clinical development was discontinued by its developers (Acceleron and Shire), and ACE-031 is not approved for therapeutic use.
Availability: Only available through research or underground labs, often sold as a “research chemical” with no regulatory oversight.
Side Effects: Mild reactions include injection site pain, headaches, fatigue, and skin rashes. Serious adverse events like nose and gum bleeds were reported in some trials.
Despite its potential, ACE-031 remains experimental, and its use outside clinical trials is not medically recommended.

Related products